Literature DB >> 29709784

Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study.

Suresh P Sulochana1, Neeraj Kumar Saini1, Prasanthi Daram1, Sai Babu Polina2, Ramesh Mullangi3.   

Abstract

A sensitive and rapid LC-MS/MS method was developed and validated for the simultaneous quantitation of enzalutamide, N-desmethylenzalutamide (active metabolite of enzalutamide), apalutamide, darolutamide and ORM-15341 (active metabolite of darolutamide) in mice plasma as per regulatory guidelines. The analytes and the internal standard (I.S.: apalutamide-d3) were extracted from 50 μL mice plasma by simple protein precipitation using acetonitrile, followed by chromatographic separation using an Atlantis C18 column with an isocratic mobile (0.2% formic acid:acetonitrile; 30:70, v/v) at a flow rate of 0.8 mL/min within 2.5 min. Detection and quantitation was done by multiple reaction monitoring on a triple quadrupole mass spectrometer following the transitions: m/z 465 → 209, 451 → 195, 478 → 450, 399 → 178, 397 → 194 and 481 → 453 for enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide, ORM-15341 and the I.S. respectively. The calibration curves were linear from 1.07 to 2000 ng/mL with r2 ≥0.99 for all the analytes. The intra- and inter-batch accuracy and precision (% CV) across quality controls varied from 88.5-111% and 1.13-13.1, 85.4-106% and 3.15-14.3, respectively for all the analytes. All the analytes were found to be stable under different conditions. The method was applied to an intravenous pharmacokinetic study in mice.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apalutamide; Darolutamide; Enzalutamide; LC–MS/MS; Method validation; Mice plasma; N-desmethylenzalutamide; ORM-15341; Pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 29709784     DOI: 10.1016/j.jpba.2018.04.038

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Utility of green chemistry for native spectrofluorimetric quantification of darolutamide as a modern anti-neoplastic drug in its market form and biological fluids.

Authors:  Hesham Salem; Amany Abdelaziz; Mai R Mekawy; Mohamed M Mahmoud; Kerolos Wissa; Doaa Fisal; Mahmoud A Abdelmajed
Journal:  RSC Adv       Date:  2022-03-31       Impact factor: 4.036

2.  Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.

Authors:  Jinge Zhao; Shu Ning; Wei Lou; Joy C Yang; Cameron M Armstrong; Alan P Lombard; Leandro S D'Abronzo; Christopher P Evans; Allen C Gao; Chengfei Liu
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.